CONTEXT: Frailty, a syndrome of multiple morbidity, weakness, and immobility in aging, is an increasingly urgent threat to public health. Single measures of low serum androgen have been associated with frailty in men, but the contributory role of hormonal changes with time is unassessed. OBJECTIVE: The objective of the study was to examine, using longitudinal measurements, the relations of serum androgens, estrogens, gonadotropins, and SHBG to the prevalence and progression of frailty in older men. DESIGN: Concord Health and Ageing in Men Project is an observational cohort study of 1705 men (aged 70 yr or older) living in the suburb of Concord, Sydney, Australia. Measurements were obtained at baseline (2005-2007) and 2-yr follow-up (2007-2009). Testosterone (T), dihydrotestosterone, estradiol, and estrone were obtained by liquid chromatography-tandem mass spectrometry, whereas SHBG, LH, and FSH were measured by immunoassay. SETTING: Subjects from the general community were sampled. PARTICIPANTS: A total of 1645 subjects constituting a representative sample of community-dwelling men aged 70 yr old or older participated in the study. OUTCOME MEASURES: The frailty syndrome was measured according to the Cardiovascular Health Study (CHS) and Study of Osteoporotic Fractures (SOF) indices. RESULTS: Androgens and estrogens showed significant age-adjusted associations with concurrent frailty. Subjects in the lowest T quintile had 2.2-fold odds of exhibiting greater CHS frailty as compared with the highest T quintile (P < 0.001); results for dihydrotestosterone, estradiol, estrone, and calculated free T were similar, and were unchanged when the SOF frailty index was substituted for the CHS frailty index. A 1 sd, 2-yr decrease in T, calculated free T, or LH was associated with a 1.2- to 1.3-fold increase in the odds of progression (increase in severity) of frailty. The control for comorbid medical conditions did not affect results. CONCLUSIONS: Age-related changes in blood androgens and estrogens may contribute to the development or progression of frailty in men.
CONTEXT: Frailty, a syndrome of multiple morbidity, weakness, and immobility in aging, is an increasingly urgent threat to public health. Single measures of low serum androgen have been associated with frailty in men, but the contributory role of hormonal changes with time is unassessed. OBJECTIVE: The objective of the study was to examine, using longitudinal measurements, the relations of serum androgens, estrogens, gonadotropins, and SHBG to the prevalence and progression of frailty in older men. DESIGN: Concord Health and Ageing in Men Project is an observational cohort study of 1705 men (aged 70 yr or older) living in the suburb of Concord, Sydney, Australia. Measurements were obtained at baseline (2005-2007) and 2-yr follow-up (2007-2009). Testosterone (T), dihydrotestosterone, estradiol, and estrone were obtained by liquid chromatography-tandem mass spectrometry, whereas SHBG, LH, and FSH were measured by immunoassay. SETTING: Subjects from the general community were sampled. PARTICIPANTS: A total of 1645 subjects constituting a representative sample of community-dwelling men aged 70 yr old or older participated in the study. OUTCOME MEASURES: The frailty syndrome was measured according to the Cardiovascular Health Study (CHS) and Study of Osteoporotic Fractures (SOF) indices. RESULTS: Androgens and estrogens showed significant age-adjusted associations with concurrent frailty. Subjects in the lowest T quintile had 2.2-fold odds of exhibiting greater CHS frailty as compared with the highest T quintile (P < 0.001); results for dihydrotestosterone, estradiol, estrone, and calculated free T were similar, and were unchanged when the SOF frailty index was substituted for the CHS frailty index. A 1 sd, 2-yr decrease in T, calculated free T, or LH was associated with a 1.2- to 1.3-fold increase in the odds of progression (increase in severity) of frailty. The control for comorbid medical conditions did not affect results. CONCLUSIONS: Age-related changes in blood androgens and estrogens may contribute to the development or progression of frailty in men.
Authors: Huanguang Jia; Charles T Sullivan; Sean C McCoy; Joshua F Yarrow; Matthew Morrow; Stephen E Borst Journal: World J Clin Cases Date: 2015-04-16 Impact factor: 1.337
Authors: Alden L Gross; Michelle C Carlson; Nadia M Chu; Mara A McAdams-DeMarco; Dan Mungas; Eleanor M Simonsick; Ravi Varadhan; Qian-Li Xue; Jeremy Walston; Karen Bandeen-Roche Journal: Mech Ageing Dev Date: 2020-05-11 Impact factor: 5.432
Authors: Monika Eichholzer; Aline Barbir; Shehzad Basaria; Adrian S Dobs; Manning Feinleib; Eliseo Guallar; Andy Menke; William G Nelson; Nader Rifai; Elizabeth A Platz; Sabine Rohrmann Journal: Aging Male Date: 2012-07-23 Impact factor: 5.892
Authors: Jonathan Afilalo; Karen P Alexander; Michael J Mack; Mathew S Maurer; Philip Green; Larry A Allen; Jeffrey J Popma; Luigi Ferrucci; Daniel E Forman Journal: J Am Coll Cardiol Date: 2013-11-27 Impact factor: 24.094